ENTITY
New Horizon Health

New Horizon Health (6YZ GR)

61
Analysis
Health Care • China
New Horizon Health Limited is a China-based investment holding company focused on early cancer screening and in-home testing, with an emphasis on colorectal, gastric, and cervical cancers. Its key products include ColoClear and Pupu Tube. The company was founded in 2015 and is headquartered in Hangzhou, China.
more
bullish•Tencent
•21 Feb 2021 10:22

ECM Weekly (21 February 2021) - Tencent Lock-Up Expiry, SciClone Pharma, Joinn Lab, Bairong, Betta

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.

Share
•19 Feb 2021 19:54

New Horizon Health IPO Trading Update: A Blockbuster IPO but It’s Time You Plan an Exit Strategy

New Horizon Health (NHH), the pioneer in China’s colorectal cancer screening market started trading on the Hong Stock Exchange on 18th February. T

Share
•17 Feb 2021 18:09

New Horizon Health IPO: Trading Debut

New Horizon opened 1.2x higher at HK$58.40 in the grey market and last stood at HK$79. Our DCF sensitivity analysis shows that the grey market...

Logo
471 Views
Share
•17 Feb 2021 10:12

New Horizon Health (诺辉健康) IPO Trading: Supply-Demand Imbalance

The sentiment is strong for both retail books and institutional book. There are strong demands from the institution side and the supply is scarce....

Logo
410 Views
Share
•15 Feb 2021 15:22

SciClone Pharmaceutical IPO: Future Prospects for Zadaxin Troubling

SciClone Pharmaceuticals, a biopharmaceutical company with an integrated platform for product development and commercialisation has filed for an...

Share
x